Three amino acids, one copper complex.
GHK stands for glycine, histidine and lysine. In GHK-Cu, the peptide binds copper. Binding a metal this way is called chelation. Free GHK, copper salts and GHK-Cu are related materials, but an experiment using one does not establish the effect of the others.
GHK has been identified in human biological fluids and studied in tissue-repair biology. Its presence in the body is a reason for scientific interest, not evidence that any manufactured preparation or route is safe.
What the matrix studies examine.
Work in cultured cells and experimental wounds examines collagen production, glycosaminoglycans—the sugar chains that help hold water—and changes in matrix-degrading enzymes. Researchers also study gene-expression patterns associated with inflammation and repair.
TGF-beta and Smad are names for a signalling system involved in collagen production and fibrosis. GHK-Cu research discusses this system alongside MMPs, enzymes that cut matrix proteins, and TIMPs, their natural inhibitors. The important question is balanced remodelling, not simply the largest increase in one marker.
Copper also participates in normal enzyme activity, including the cross-linking enzyme lysyl oxidase. That role does not establish that extra copper or a copper-peptide preparation corrects a deficiency. The chemical state and exposure remain relevant.
Topical findings belong to the tested formulation.
The earlier source set includes discussion of facial skin appearance, wound healing, fibroblast behaviour and gene data. It also includes animal work. These strands should remain separate: a cell-culture result is not a measured improvement in a person.
Topical studies described changes in skin appearance and matrix-related measurements. However, a cream can contain several active ingredients and a vehicle that changes hydration by itself. Small studies and limited long-term follow-up constrain conclusions about durability and rare harms.
Hair, scar and post-procedure applications were also discussed in the earlier edition. They do not form one interchangeable indication. A hair-density outcome, wound-closure endpoint and facial wrinkle measurement need their own controls and source records.
Six contexts, six different questions.
| Context | Route discussed in the older account | What needs to be established |
|---|---|---|
| Mild photoageing | Topical | A controlled comparison of the complete formulation. |
| More marked photoageing | Topical | Baseline severity and meaningful measured change. |
| After an ablative procedure | Topical on disrupted skin | Safety and benefit in that particular wound setting. |
| Scar remodelling | Intradermal research context | Route-specific human safety and scar outcomes. |
| Hair research | Topical scalp formulations | Hair-density and shaft measurements, with controls. |
| Microneedling adjunct | Barrier-disrupting combination | An effect beyond the procedure and its vehicle. |
Each context needs its own evidence. Changing the route or disrupting the skin barrier changes the question.
Stability and penetration can change the answer.
Light, temperature, acidity, oxidants and other ingredients can affect the complex. Carrier systems and penetration-enhancement methods are therefore studied alongside the peptide itself. A formulation’s appearance or blue colour cannot establish identity, concentration or suitability for an intended route.
Electrical and ultrasonic delivery methods appeared in the old account, as did microneedling. They are delivery research questions here. They cannot be inferred to have the same safety profile as application to intact skin.
Cosmetic use and injectable status are separate.
Topical copper tripeptide-1 appears in cosmetic products. Cosmetic use does not establish FDA drug approval or the safety of injectable GHK-Cu.
On FDA’s page with content current as of April 22, 2026, GHK-Cu for injectable routes is listed as nominated but withdrawn. Withdrawal is not clearance, approval for compounding or a finding that safety concerns have been resolved.
Local irritation, allergy, copper-handling disorders, interactions and missing data in pregnancy, childhood or long-term exposure remain relevant safety questions. The older claims of near-universal tolerability cannot establish safety across these populations or routes.
What a stronger evidence base would add.
Independent replication, transparent formulation details, well-chosen controls and longer follow-up would make comparisons more useful. Human exposure measurements would also help connect a laboratory concentration with the conditions in skin.
Cell, animal and topical studies address different questions. They cannot establish retail treatment models, prices or guarantees.
Sources & further reading
Bibliography
- Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev . 2012;2012:324832. doi:10.1155/2012/324832
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed . 2008;19(8):969-988. doi:10.1163/156856208784909435
- Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis . 2010;27(2):83-90. doi:10.1007/s10585-010-9305-4
- Appa Y, Stephens TJ, Wickett RR. A split-face study to evaluate the improvement of skin condition when using a facial cream containing peptide complex and cosmetic actives. J Cosmet Dermatol . 2012;11(4):294-301. doi:10.1111/jocd.12005
- Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg . 2005;7(1):27-31. doi:10.1001/archfaci.7.1.27
- Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest . 1993;92(5):2368-2376. doi:10.1172/JCI116842
- Siméon A, Monier F, Emonard H, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol . 1999;112(6):957-964. doi:10.1046/j.1523-1747.1999.00606.x
- Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. In: Elsner P, Maibach HI, eds. Cosmeceuticals and Active Cosmetics . 2nd ed. Taylor & Francis; 2005:549-563.
- Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen . 1994;2(4):259-269. doi:10.1046/j.1524-475X.1994.20406.x
- Cangul IT, Gul NY, Topal A, Yilmaz R. Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol . 2006;17(6):417-423. doi:10.1111/j.1365-3164.2006.00548.x
- Downey D, Larrabee WF Jr, Voci V, Kim J. The effect of the tripeptide-copper complex on the healing of split-thickness skin graft donor sites. Arch Facial Plast Surg . 1999;1(3):195-197.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci . 2018;19(7):1987. doi:10.3390/ijms19071987